Indegene has announced the appointment of Jill Mary De Simone as an Additional Director (Non-Executive Independent Director), effective January 22, 2026. The appointment is subject to shareholder approval and is for a term of three years, expiring January 21, 2029. Ms. De Simone brings extensive biopharmaceutical and board leadership experience to Indegene.
New Independent Director
Indegene Limited has appointed Jill Mary De Simone as an Additional Director (Non-Executive Independent Director) to its Board, effective January 22, 2026. This decision was made based on the recommendation of the Nomination and Remuneration Committee and approved by the Board of Directors.
Appointment Details and Tenure
Ms. De Simone’s appointment is for a term of three years, commencing on January 22, 2026, and concluding on January 21, 2029. The appointment is subject to the approval of the company’s shareholders.
Director’s Background
Ms. De Simone brings substantial experience as a biopharmaceutical executive and board director. Previously President of U.S. Oncology at Merck, she held leadership positions at Merck, Teva, and Bristol Myers Squibb. She has extensive experience in driving growth, innovation, and governance within global healthcare organizations, launching transformative therapies. She currently advises companies on commercialization and leadership transitions.
Independence Declaration
The company has affirmed that Ms. De Simone is not debarred from holding the office of Director by any regulatory authority. She is also not related to any existing Director of the company.
Source: BSE
